[Business Wire] – Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the second quarter ended June 30, 2016 on Thursday, July 28, 2016 before the US financial markets open. Read more on this. Alexion Pharmaceuticals, Inc. (ALXN) , valued at $28.19B, started trading this morning at $126.03. Looking at the stock, its one day range is $124.01 to $126.35 with a trailing 52-week range being $110.56 to $208.88. ALXN shares are currently priced at 24.64x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 5.67x earnings multiple for the same period. Consensus earnings for the current quarter by the 19 sell-side analysts covering the stock is an estimate of $1.18 per share, which would be $0.26 worse than the year-ago quarter and a $0.07 sequential decrease. The full-year EPS estimate is $5.05, which would be a $0.06 better than last year. The quarterly earnings estimate is predicated on a consensus revenue forecast of $743.18 Million. If reported, that would be a 16.81% increase over the year-ago quarter. In terms of ratings, Citigroup upgraded ALXN from Neutral to Buy (Jun 27, 2016). Previously, Robert W. Baird downgraded ALXN from Outperform to Neutral. When considering if perhaps the stock is under or overvalued, the average price target is $185.83, which is 47.45% above where the stock opened this morning. See more in (NASDAQ:ALXN) Similar Articles: Market Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Alexion Pharmaceuticals, Inc. — ALXN Market Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Alexion Pharmaceuticals to Report First Quarter 2016 Results on Thursday, April 28, 2016 Stock Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Results on Wednesday, February 3, 2016